EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Potential drug repurposing of ruxolitinib to inhibit the JAK / STAT pathway for the treatment of patients with epithelial ovarian cancer

Irfan Yunianto iD, Margaret Currie, Kenny Chitcholtan, Peter Sykes

Journal of Obstetrics and Gynaecology Research · 2023

DOI: 10.1111/jog.15761 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2023. Verfasst von Irfan Yunianto und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, University of Otago, Christchurch, New Zealand. Hauptthemen laut MEDLINE: Janus Kinases, Ovarian Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of Otago.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

This review aimed to describe the potential for therapeutic targeting of the JAK/STAT signaling pathway by repurposing the clinically‐approved JAK inhibitor ruxolitinib in the patients with epithelial ovarian cancer (OC) setting.

Methods

We reviewed publications that focus on the inhibition of the JAK/STAT pathway in hematological and solid malignancies including OC.

Results

Preclinical studies showed that ruxolitinib effectively reduces OC cell viability and metastasis and enhances the anti‐tumor activity of chemotherapy drugs. There are a number of recent clinical trials exploring the role of JAK/STAT inhibition in solid cancers including OC. Early results have not adequately supported efficacy in solid tumors. However, there are preclinical data and clinical studies supporting the use of ruxolitinib in combination with both chemotherapy and other targeted drugs in OC setting.

Conclusion

Inflammatory conditions and persistent activation of the JAK/STAT pathway are associated with tumourigenesis and chemoresistance, and therapeutic blockade of this pathway shows promising results. For women with OC, clinical investigation exploring the role of ruxolitinib in combination with chemotherapy agents or other targeted therapeutics is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus KinasesOvarian NeoplasmsHumansFemaleDrug RepositioningCarcinoma, Ovarian EpithelialSTAT Transcription FactorsSignal TransductionNitrilesPyrazolesPyrimidines

Stichwörter der Autor:innen

JAK/STATascitic fluidchemoresistanceovarian cancerruxolitinib

Substanzen

Janus KinasesSTAT Transcription FactorsruxolitinibNitrilesPyrazolesPyrimidines

Autor:innen und Institutionen

  • Department of Obstetrics and Gynaecology, University of Otago, Christchurch, New Zealand.
  • Department of Biology Education, Universitas Ahmad Dahlan, Indonesia.
  • Department of Pathology and Biomedical Sciences, University of Otago, Christchurch, New Zealand.

ORCID-Profile: Irfan Yunianto

Förderung

  • University of Otago

Zitieren

APA

Yunianto, I., Currie, M., Chitcholtan, K., & Sykes, P. (2023). Potential drug repurposing of ruxolitinib to inhibit the JAK / STAT pathway for the treatment of patients with epithelial ovarian cancer. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.15761

Vancouver

Yunianto I, Currie M, Chitcholtan K, Sykes P. Potential drug repurposing of ruxolitinib to inhibit the JAK / STAT pathway for the treatment of patients with epithelial ovarian cancer. Journal of Obstetrics and Gynaecology Research. 2023. doi:10.1111/jog.15761

BibTeX
@article{Yunianto2023,
  author = {Yunianto, Irfan and Currie, Margaret and Chitcholtan, Kenny and Sykes, Peter},
  title = {Potential drug repurposing of ruxolitinib to inhibit the JAK / STAT pathway for the treatment of patients with epithelial ovarian cancer},
  journal = {Journal of Obstetrics and Gynaecology Research},
  year = {2023},
  doi = {10.1111/jog.15761}
}
Kostenlos starten →